These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21543316)

  • 41. The vaccinia-related kinases phosphorylate the N' terminus of BAF, regulating its interaction with DNA and its retention in the nucleus.
    Nichols RJ; Wiebe MS; Traktman P
    Mol Biol Cell; 2006 May; 17(5):2451-64. PubMed ID: 16495336
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Kinetic properties of p53 phosphorylation by the human vaccinia-related kinase 1.
    Barcia R; López-Borges S; Vega FM; Lazo PA
    Arch Biochem Biophys; 2002 Mar; 399(1):1-5. PubMed ID: 11883897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Members of a novel family of mammalian protein kinases complement the DNA-negative phenotype of a vaccinia virus ts mutant defective in the B1 kinase.
    Boyle KA; Traktman P
    J Virol; 2004 Feb; 78(4):1992-2005. PubMed ID: 14747564
    [TBL] [Abstract][Full Text] [Related]  

  • 44. VRK1 phosphorylates CREB and mediates CCND1 expression.
    Kang TH; Park DY; Kim W; Kim KT
    J Cell Sci; 2008 Sep; 121(Pt 18):3035-41. PubMed ID: 18713830
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of a dominant epitope in human vaccinia-related kinase 1 (VRK1) and detection of different intracellular subpopulations.
    Valbuena A; López-Sánchez I; Vega FM; Sevilla A; Sanz-García M; Blanco S; Lazo PA
    Arch Biochem Biophys; 2007 Sep; 465(1):219-26. PubMed ID: 17617371
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines.
    Blanco S; Klimcakova L; Vega FM; Lazo PA
    FEBS J; 2006 Jun; 273(11):2487-504. PubMed ID: 16704422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mitogen-activated protein kinases interacting kinases are autoinhibited by a reprogrammed activation segment.
    Jauch R; Cho MK; Jäkel S; Netter C; Schreiter K; Aicher B; Zweckstetter M; Jäckle H; Wahl MC
    EMBO J; 2006 Sep; 25(17):4020-32. PubMed ID: 16917500
    [TBL] [Abstract][Full Text] [Related]  

  • 48. VRK1 regulates Cajal body dynamics and protects coilin from proteasomal degradation in cell cycle.
    Cantarero L; Sanz-García M; Vinograd-Byk H; Renbaum P; Levy-Lahad E; Lazo PA
    Sci Rep; 2015 Jun; 5():10543. PubMed ID: 26068304
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ras-PI3K pathway promotes osteosarcoma progression via regulating VRK1-mediated H2A phosphorylation at threonine 120.
    Xu X; Yu H
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4274-4283. PubMed ID: 31810390
    [No Abstract]   [Full Text] [Related]  

  • 50. Vaccinia-related kinase 1 (VRK1) is an upstream nucleosomal kinase required for the assembly of 53BP1 foci in response to ionizing radiation-induced DNA damage.
    Sanz-García M; Monsalve DM; Sevilla A; Lazo PA
    J Biol Chem; 2012 Jul; 287(28):23757-68. PubMed ID: 22621922
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition.
    Lee N; Kwon JH; Kim YB; Kim SH; Park SJ; Xu W; Jung HY; Kim KT; Wang HJ; Choi KY
    Oncotarget; 2015 Oct; 6(30):30130-48. PubMed ID: 26375549
    [TBL] [Abstract][Full Text] [Related]  

  • 52. VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma.
    Santos CR; Rodríguez-Pinilla M; Vega FM; Rodríguez-Peralto JL; Blanco S; Sevilla A; Valbuena A; Hernández T; van Wijnen AJ; Li F; de Alava E; Sánchez-Céspedes M; Lazo PA
    Mol Cancer Res; 2006 Mar; 4(3):177-85. PubMed ID: 16547155
    [TBL] [Abstract][Full Text] [Related]  

  • 53. VRK1 Is a Synthetic-Lethal Target in VRK2-Deficient Glioblastoma.
    Shields JA; Meier SR; Bandi M; Mulkearns-Hubert EE; Hajdari N; Ferdinez MD; Engel JL; Silver DJ; Shen B; Zhang W; Hubert CG; Mitchell K; Shakya S; Zhao SC; Bejnood A; Zhang M; Tjin Tham Sjin R; Wilker E; Lathia JD; Andersen JN; Chen Y; Li F; Weber B; Huang A; Emmanuel N
    Cancer Res; 2022 Nov; 82(21):4044-4057. PubMed ID: 36069976
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The human VRK1 chromatin kinase in cancer biology.
    Campillo-Marcos I; García-González R; Navarro-Carrasco E; Lazo PA
    Cancer Lett; 2021 Apr; 503():117-128. PubMed ID: 33516791
    [TBL] [Abstract][Full Text] [Related]  

  • 55. VRK1 chromatin kinase phosphorylates H2AX and is required for foci formation induced by DNA damage.
    Salzano M; Sanz-García M; Monsalve DM; Moura DS; Lazo PA
    Epigenetics; 2015; 10(5):373-83. PubMed ID: 25923214
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The 3D solution structure of the C-terminal region of Ku86 (Ku86CTR).
    Harris R; Esposito D; Sankar A; Maman JD; Hinks JA; Pearl LH; Driscoll PC
    J Mol Biol; 2004 Jan; 335(2):573-82. PubMed ID: 14672664
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NMR studies of interactions between C-terminal tail of Kir2.1 channel and PDZ1,2 domains of PSD95.
    Pegan S; Tan J; Huang A; Slesinger PA; Riek R; Choe S
    Biochemistry; 2007 May; 46(18):5315-22. PubMed ID: 17437338
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathogenic effects of Leu200Pro and Arg387His VRK1 protein variants on phosphorylation targets and H4K16 acetylation in distal hereditary motor neuropathy.
    Campos-Díaz A; Morejón-García P; Monte-Serrano E; Ros-Pardo D; Marcos-Alcalde I; Gómez-Puertas P; Lazo PA
    J Mol Med (Berl); 2024 Jun; 102(6):801-817. PubMed ID: 38554151
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study.
    Del Puerto-Nevado L; Marin-Arango JP; Fernandez-Aceñero MJ; Arroyo-Manzano D; Martinez-Useros J; Borrero-Palacios A; Rodriguez-Remirez M; Cebrian A; Gomez Del Pulgar T; Cruz-Ramos M; Carames C; Lopez-Botet B; Garcia-Foncillas J
    BMC Cancer; 2016 Jul; 16():519. PubMed ID: 27456229
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Unique activation mechanism of protein kinase CK2. The N-terminal segment is essential for constitutive activity of the catalytic subunit but not of the holoenzyme.
    Sarno S; Ghisellini P; Pinna LA
    J Biol Chem; 2002 Jun; 277(25):22509-14. PubMed ID: 11956194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.